Literature DB >> 16530522

Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones.

Teresa Pollicino1, Laura Belloni, Giuseppina Raffa, Natalia Pediconi, Giovanni Squadrito, Giovanni Raimondo, Massimo Levrero.   

Abstract

BACKGROUND & AIMS: HBV covalently closed circular DNA (cccDNA), the replicative intermediate responsible for persistent HBV infection of hepatocytes, is the template for transcription of all viral mRNAs. Nuclear cccDNA accumulates as a stable episome organized into minichromosomes by histone and nonhistone proteins. In this study we investigated, by a newly developed sensitive and specific assay, the relationship between viral replication and HBV chromatin assembly, transcription, and interaction with viral and cellular regulatory proteins.
METHODS: To achieve this aim we coupled a quantitative chromatin immunoprecipitation (ChIP) technique to an established method that allows the amplification of virion-encapsidated HBV genomes after transfection of linear HBV DNA into human hepatoma HuH7 cells. The cccDNA-ChIP technique was also applied to study HBV minichromosome transcriptional regulation in liver tissue from HBV-infected patients.
RESULTS: The use of anti-acetyl-H4/-H3 specific antibodies to immunoprecipitate transcriptionally active chromatin revealed that HBV replication is regulated by the acetylation status of the cccDNA-bound H3/H4 histones. Class I histone deacetylases inhibitors induced an evident increase of both cccDNA-bound acetylated H4 and HBV replication. Finally, histones hypoacetylation and histone deacetylase 1 recruitment onto the cccDNA in liver tissue correlated with low HBV viremia in hepatitis B patients.
CONCLUSIONS: We developed a ChIP-based assay to analyze, in vitro and ex vivo, the transcriptional regulation of HBV cccDNA minichromosome. Our results provide new insights on the regulation of HBV replication and identify the enzymatic activities that modulate the acetylation of cccDNA-bound histones as new therapeutic targets for anti-HBV drugs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16530522     DOI: 10.1053/j.gastro.2006.01.001

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  160 in total

1.  IFN-α inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome.

Authors:  Laura Belloni; Lena Allweiss; Francesca Guerrieri; Natalia Pediconi; Tassilo Volz; Teresa Pollicino; Joerg Petersen; Giovanni Raimondo; Maura Dandri; Massimo Levrero
Journal:  J Clin Invest       Date:  2012-01-17       Impact factor: 14.808

2.  Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation.

Authors:  Dawei Cai; Courtney Mills; Wenquan Yu; Ran Yan; Carol E Aldrich; Jeffry R Saputelli; William S Mason; Xiaodong Xu; Ju-Tao Guo; Timothy M Block; Andrea Cuconati; Haitao Guo
Journal:  Antimicrob Agents Chemother       Date:  2012-05-29       Impact factor: 5.191

Review 3.  Present and future therapies of hepatitis B: From discovery to cure.

Authors:  T Jake Liang; Timothy M Block; Brian J McMahon; Marc G Ghany; Stephan Urban; Ju-Tao Guo; Stephen Locarnini; Fabien Zoulim; Kyong-Mi Chang; Anna S Lok
Journal:  Hepatology       Date:  2015-10-27       Impact factor: 17.425

4.  Hepatitis: Epigenetic control of HBV by HBx protein--releasing the break?

Authors:  Ulrike Protzer
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-09-01       Impact factor: 46.802

Review 5.  Metabolism and function of hepatitis B virus cccDNA: Implications for the development of cccDNA-targeting antiviral therapeutics.

Authors:  Ju-Tao Guo; Haitao Guo
Journal:  Antiviral Res       Date:  2015-08-10       Impact factor: 5.970

6.  Methyltransferase PRMT1 is a binding partner of HBx and a negative regulator of hepatitis B virus transcription.

Authors:  Shirine Benhenda; Aurélie Ducroux; Lise Rivière; Bijan Sobhian; Michael D Ward; Sarah Dion; Olivier Hantz; Ulrike Protzer; Marie-Louise Michel; Monsef Benkirane; Oliver J Semmes; Marie-Annick Buendia; Christine Neuveut
Journal:  J Virol       Date:  2013-02-06       Impact factor: 5.103

Review 7.  Revisiting Hepatitis B Virus: Challenges of Curative Therapies.

Authors:  Jianming Hu; Ulrike Protzer; Aleem Siddiqui
Journal:  J Virol       Date:  2019-09-30       Impact factor: 5.103

8.  Recombinant covalently closed circular hepatitis B virus DNA induces prolonged viral persistence in immunocompetent mice.

Authors:  Zhihua Qi; Gaiyun Li; Hao Hu; Chunhui Yang; Xiaoming Zhang; Qibin Leng; Youhua Xie; Demin Yu; Xinxin Zhang; Yueqiu Gao; Ke Lan; Qiang Deng
Journal:  J Virol       Date:  2014-05-07       Impact factor: 5.103

9.  Antiviral Properties and Mechanism of Action Studies of the Hepatitis B Virus Capsid Assembly Modulator JNJ-56136379.

Authors:  Jan Martin Berke; Pascale Dehertogh; Karen Vergauwen; Wendy Mostmans; Koen Vandyck; Pierre Raboisson; Frederik Pauwels
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

10.  Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series report.

Authors:  David Ritchie; Richard L Piekarz; Piers Blombery; Laszlo J Karai; Stefania Pittaluga; Elaine S Jaffe; Mark Raffeld; John E Janik; H Miles Prince; Susan E Bates
Journal:  Haematologica       Date:  2009-07-16       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.